

July 13, 2021



# Unicycive Therapeutics Announces Pricing of Initial Public Offering

LOS ALTOS, Calif., July 13, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the pricing of its underwritten initial public offering of 5,000,000 units at a public offering price per unit of \$5.00. Each unit consists of one share of common stock and four-fifths of a warrant to purchase one share of common stock. The warrants have an exercise price of \$6.00 per share and are exercisable for a period of five years after the issuance date. All of the units are being offered by Unicycive. In addition, Unicycive has granted the underwriters a 45-day option to purchase up to an additional 750,000 shares of its common stock and/or warrants to purchase up to an additional 600,000 shares of its common stock, at the initial public offering price, less the underwriting discounts and commissions.

In connection with the offering, the Company's common stock has been approved for listing on The Nasdaq Capital Market. The shares are expected to begin trading on the Nasdaq Capital Market on July 13, 2021, under the ticker symbol "UNCY." The offering is expected to close on July 15, 2021, subject to customary closing conditions.

The gross proceeds to Unicycive from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be \$25 million.

Roth Capital Partners is acting as the sole manager for the offering.

The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (Registration No. 333-256367) that was previously filed with the U.S. Securities and Exchange (the "SEC") and declared effective on July 12, 2021. This offering is being made only by means of a prospectus. A preliminary prospectus relating to and describing the terms of the offering has been filed with the SEC. Copies of the preliminary prospectus can be accessed through the SEC's website at [www.sec.gov](http://www.sec.gov). Copies of the final prospectus relating to the initial public offering can be obtained, when available, through the SEC's website at [www.sec.gov](http://www.sec.gov) or from: Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660, Attention: Equity Capital Markets at (800) 678-9147 or by email [atrothecm@roth.com](mailto:atrothecm@roth.com).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

## About Unicycive

Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late

preclinical development for the treatment of acute kidney injury. For more information, please visit [www.unicycive.com](http://www.unicycive.com).

### **Forward-looking statement**

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. Our forward-looking statements reflect our current views with respect to future events and are based on currently available information. These risks and uncertainties, many of which are beyond our control, include: the risk that the initial public offering of common stock may not close, as well as other risks described in the section entitled "Risk Factors" in the prospectus, which can be obtained on the SEC website at [www.sec.gov](http://www.sec.gov). Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

### **Contacts:**

Remy Bernarda  
[ir@unicycive.com](mailto:ir@unicycive.com)  
(650) 900-5470

 View original content to download multimedia <https://www.prnewswire.com/news-releases/unicycive-therapeutics-announces-pricing-of-initial-public-offering-301332571.html>

SOURCE Unicycive Therapeutics Inc.